Q-omics provides the consensus-scored ELOCP22 profile across patient tissues and cancer cell-line models. ELOCP22 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ELOCP22 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, ELOCP22 RNA expression shows 5,332 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight READ, THCA, and KIRC as cancer lineages where ELOCP22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP22 survival associations across molecular data types. ELOCP22 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP22 RNA expression–survival associations across cancer types. High ELOCP22 expression shows unfavorable associations in READ, BRCA, COAD, SKCM, MESO and ACC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify READ as the clearest survival context for ELOCP22 RNA expression.
This table summarizes ELOCP22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP22 shows lower tumor expression in THCA and higher tumor expression in COAD. The THCA box plot shows higher ELOCP22 RNA expression in normal versus tumor tissue (log2 FC = −0.064, t-test p = .018).
This table shows molecular features associated with ELOCP22 in patient tissues and cancer cell lines. In patient samples, ELOCP22 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
